O. Sitbon (Clamart, France), S. Kostianev (Plovdiv, Bulgaria)
Sildenafil increases exercise capacity by alleviation of hypoxic pulmonary hypertension at low altitude and at Mount Everest base camp
H. A. Ghofrani, F. Reichenberger, M. G. Kohstall, E. Mrosek, T. Seeger, W. Seeger, F. Grimminger (Giessen, Germany)
|  |
Pharmacokinetic differences between inhaled treprostinil and inhaled iloprost in severe pulmonary hypertension
R. Voswinckel, B. Enke, M. G. Kohstall, T. Gessler, F. Reichenberger, A. Ghofrani, W. Seeger, H. Olschewski (Giessen, Germany)
| |
Inhaled iloprost in HIV-related pulmonary arterial hypertension
H. A. Ghofrani, G. Friese, T. Discher, H. Olschewski, R. T. Schermuly, N. Weissmann, W. Seeger, F. Grimminger, J. Lohmeyer (Giessen, Germany)
| |
Efficacy of sitaxsentan, an endothelin-A receptor antagonist in PAH in traditional vs. expanded study populations
A. Frost, D. Langleben, R. Barst & the STRIDE 1 Study Group (Houston, United States Of America; Montreal, Canada; United States of America)
| |
Epoprostenol (EPT) for acute reactivity testing (AVT) in pulmonary artery hypertension (PAH)
C. Marini, B. Formichi, G. Di Ricco, L. Tonelli, C. Bauleo (Pisa, Italy)
| |
Safety of switching from different prostanoids in the treatment of idiopathic pulmonary hypertension
J. Guerra, V. Monforte, C. Bravo, A. Roman (Barcelona, Spain)
| |
Sildenafil for patients with portopulmonary hypertension, candidates to hepatic transplant
E. Garcia, A. Brandao (Porto Alegre, Brazil)
| |
Hemodynamic correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension
H. J. Reesink, R. Lutter, J. J. Kloek, H. M. Jansen, P. Bresser (Amsterdam, The Netherlands)
| |
Dexamethasone and tadalafil prophylaxis prevents both excessive pulmonary constriction and high altitude pulmonary edema in susceptible subjects
M. Maggiorini, H. P. Brunner-La Rocca, P. Bärtsch, M. Fischler, T. Böhm, K. E. Bloch, H. Mairbäurl (Zurich, Basel, Switzerland; Heidelberg, Germany)
| |
Estimation of effects of intermittent exposure to the altitude of 3200m on hypoxic pulmonary vasoreactivity
A. M. Maripov, A. S. Sarybaev, A. S. Sydykov (Bishkek, Kyrgyzstan)
| |
NT-proBNP correlates with RVEF in patients suffering from pulmonary arterial hypertension
S. Hans-Juergen, P. Hans, F. Martin, B. Matthias, W. Hubert, T. Joachim, S. Joachim (Leipzig, Germany)
| |
Pulmonary arterial hypertension effecting cardiac external stroke work
T. J. C. Gan, T. J. Marcus, A. Boonstra, P. E. Postmus, A. Vonk Noordegraaf (Amsterdam, The Netherlands)
| |
Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension
H. H. Leuchte, R. A. Baumgartner, C. Neurohr, M. Vogeser, J. Behr (Munich, Germany)
| |
Obstructive sleep apnea can cause pulmonary hypertension in the absence of lung disease
D. Sajkov, R. D. McEvoy (Adelaide, Australia)
| |
Six-minute walk test correlates with hemodynamic severity in chronic thromboembolic pulmonary hypertension
H. J. Reesink, N. E. Verheij, J. J. Kloek, C. M. Roos, H. M. Jansen, P. Bresser (Amsterdam, The Netherlands)
| |
Pulmonary hypertension in ankylosing spondylitis
N. Karoli, A. Rebrov (Saratov, Russia)
| |
The CAMbridge pulmonary hypertension outcome review (CAMPHOR): development and validation
N. Doughty, S. P. McKenna, D. Meads, J. Pepke Zaba (Cambridge, Manchester, United Kingdom)
| |
Echocardiographic evaluation of right ventricular diastolic function in patients with chronic obstructive pulmonary disease and chronic obstructive pulmonary disease with cor pulmonale
Y. C. Ko, S. U. Lee, S. K. Cho, K. Y. Hong, T. H. Kim (Kwangju, South Korea)
| |
COPD patients have reduced bronchial blood flows
P. Paredi, S. A. Kharitonov, P. J. Barnes (London, United Kingdom)
| |